Herein, murine prostate cancer cell lines, generated via selective transduction with a single oncogene (c-Myc, Ha-Ras, and v-Src), demonstrated oncogene-specific prostate cancer molecular signatures that were recapitulated in human prostate cancer, and developed lung metastasis in immune competent mice. Interrogation of two independent retrospective cohorts of patient samples using the oncogene signature demonstrated an ability to distinguish tumor from normal prostate with a predictive value for prostate cancer of 98 -99%. In a blinded study, the signature algorithm demonstrated independent substratification of reduced recurrence free survival by Kaplan-Meier analysis. The generation of new oncogene-specific prostate cancer cell lines that recapitulate human prostate cancer gene expression, that metastasize in immunecompetent mice, are a valuable new resource for testing targeted therapy while the molecular signatures identified herein provides further value over current gene signature markers of prediction and outcome.
INTRODUCTION
Prostate cancer remains the most common non-dermatological cancer in the United States and the second leading cause of cancer death amongst men with ~190,000 new cases diagnosed and ~27,000 deaths annually. The adoption of screening with serum prostate specific antigen (PSA) has led both to the earlier detection of prostate cancer and to the improved understanding of the biological heterogeneity of the disease. Risk stratification following local therapy has used histopathological criterion, gleason scale, tumor grade, the degree of tumor differentiation, and serum PSA. The diverse clinical behavior of prostate cancer with some patients dying within 2 years of diagnosis and others living for 20 years with localized disease emphasizes the need for improved prognostic tests.
The molecular mechanisms contributing to prostate cancer recurrence and therapy resistance are poorly understood. Androgen ablation therapy results in a 60% to 80% initial response rate (1) , however ~30% of men who receive radical prostatectomy relapse, attributed to micrometastatic disease. Clinical classification nomograms are used that incorporate individual pre-and post-operative parameters. These clinically efficient models have limited value in predicting the diverse outcomes of patients with similar clinical, histological and biochemical parameters. A global pathway analysis view of the prostate cancer genome identified the most commonly altered pathways as the AR, Rb, PI3K and Ras/Raf signaling (2) . The use of gene expression analysis has identified a subset of gene clusters that correlated in retrospective analysis with therapy outcomes (3, 4) . Biomarkers derived from gene expression profiling studies that use the same data set for signature discovery and validation (5, 3, 6) typically however, demonstrated limited utility when used to re-interrogate independent data sets (7). (8) . c-Myc, which is overexpressed in human prostate cancer is sufficient to induce prostatic intraepithelial neoplasia (PIN) in transgenic mice (8) . In contrast, Ras mutations are relatively uncommon, however induction of Ras effector pathways has been revealed by microarray and genomic analysis (2) . Up-regulation of Ras-mediated signaling cascades may also reflect the overexpression of autocrine and paracrine factors (EGFR, TGFα) (9) . Although there are conflicting results over whether ErbB2 is overexpressed or amplified in prostate cancer, a subpopulation of prostate cancer patients demonstrated a gene expression pathway of activated ErbB2 signaling (10) . Activation of the Src pathway is also found in primary prostate cancer associated with a truncated version of c-kit (11) , and a subset of human prostate cancers express a Src signature (10) .
The current studies were conducted to address several key needs. Firstly, the development of new therapies for prostate cancer requires model systems that closely resemble human disease. Unfortunately, to date there have been several limitations with currently available cell lines. Although important transplantation experiments have been conducted using human prostate cancer cell lines in immune deficient animals, the immune system plays an important role in prostate cancer onset and progression (12, 13) Ras transduction has been developed that develops bone metastasis in immune-competent mice (15) . Fourthly, although the transgenic mouse had been effectively deployed as a model to study the molecular basis of human cancers the prostate cancer mouse models have long latency and often unpredictable metastasis (16) .
The current studies aimed to generate oncogene specific cell lines that could be grown in immune-competent mice, determine whether the lines recapitulate human prostate cancer and validate the signature in distinct populations of patients as a prognostic test. Herein, oncogene transduction of murine prostate epithelium induced prostate cellular transformation with invasive and metastatic properties. Oncogene-specific molecular signatures were defined that distinguished benign from malignant human prostate and predicted outcome of human prostate cancer patients. The generation of oncogene-specific prostate cancer cell lines that recapitulate molecular signatures of human prostate cancer will be of value in understanding molecular mechanisms and identification of new therapies for this disease.
Research. 
MATERIALS AND METHODS
Mice, cell culture, chemicals and reagents. The experimental procedures with transgenic mice were approved by the ethics committee of Thomas Jefferson University. Mice were in the FVB strain. Mouse prostate epithelial cell cultures were isolated from prostate glands of 12 week old male mice and maintained as previously described (17) and analyzed after 25 passages with at least three lines of each genotype. Transduction of cells by the retroviral expression vector encoding either c-Myc, Ha-Ras, v-Src, NeuT, in the vector pBABE-IRES-GFP, was previously described (18, 19) . As changes in genome copy number and/or genome structure contribute to tumor progression (20, 21) , we conducted genome copy number analysis using array CGH (see Table 1 by Ha-Ras (Supplemental Fig. 2A ). Lung metastases were characterized at autopsy by histopathological assessment as described in the Materials and Methods (Fig. 4A) of lung metastases derived from subcutaneous injection of the primary PECs was increased in the Ha-Ras, v-Src, and c-Myc sublines (Fig. 4B) .
Oncogene specific molecular signatures in prostate cancer cell lines. In order to further characterize the molecular genetic signaling pathways regulated by specific oncogenes in prostate epithelial cells, mRNA was prepared from the oncogene transformed PEC cell lines.
Microarray analysis identified a total of 2635 out of 22115 genes that were significantly altered in expression (at least two-fold change) in oncogene over-expressing cell lines when compared with non-transformed prostate epithelial cell control samples ( The murine prostate oncogene expression signature in high grade and advanced stage human prostate cancer. The prostate "oncogene expression signature" (Group 1) was defined as genes that were significantly altered in expression level and that were uniquely altered in expression by a specific oncogene compared with primary prostate epithelial cells (Fig. 5A) . ).
The heatmaps in Fig. 6B depicts the genes shared between c-Myc transduced fibroblasts (Fig. 6B) , c-Myc-induced mammary tumors (Fig. 6C) (left-hand heatmaps) (Fig. 6B) and the c-Myc-induced mammary tumors (85%) (Fig. 6C ).
Kaplan Meier analysis was used to evaluate the difference in recurrence-free survival associated with high expression versus low expression of these genes. Genes that correspond to the 14 most upregulated genes of the c-Myc signature were used to assign the samples as high transformed cell lines and survival rates from human prostate cancer, a previously published microarray dataset of human prostate tumor samples with known clinical recurrence-free survival time was used (7) . Figure 7A provides a heatmap showing the expression profiles of genes in the human prostate cancer samples from the Glinsky's data set, which was upregulated in the c-Myc (Fig. 5A, Group 8) oncogene-transformed prostate cancer cell lines.
Canonical analysis was performed using the c-Myc-specific genes that were also found to be differentially expressed between tumor and normal samples in two human prostate datasets.
The first canonical variable, resulting from this analysis, was used to discriminate tumor from normal samples in each human prostate dataset. A plot of tumor and normal samples along the first canonical variable axis revealed a pronounced separation between tumor and normal samples (Fig. 7B) . ROC curves have been used previously to evaluate the diagnostic ability of PSA (26, 27) as well as its ability to identify metastatic disease (28) . A receiver operating 
significant overlap with several recent published data sets and transgenic models of prostate cancer (8, 23) . The c-Myc signature was used to derive algorithms that distinguished normal from cancerous prostate tissue with ~99% predictive value (diagnostic signature).
Herein, transduction of primary prostate epithelial cells of FVB mice by a single oncogene was sufficient for transformation. Oncogene genomic analysis identified loss of tumor suppressor regions and amplification of additional oncogenic regions that resemble genomic changes in human prostate cancer (Fig. 2) . The cell lines reflect both AR-response and ARunresponse prostate cancers (Supplemental Fig. 6 ) although each line expresses plasma Kallikrein 1B (PK1B) (Supplemental Fig. 2B ). Kallikrein gene expression is regulated by basal and androgen-independent factors, thus PK1B in the tumors may not necessarily be correlated directly with AR expression (Fig. 1D) . The tumors all expressed CK8 while the c-Myc and v-Src lines expressed CK5, by Western blot (Fig. 1D) and by immunofluorescence in the primary cell lines (Supplemental Fig. 7A ) and in the lung metastasis (Supplemental Fig. 7B ). CK5 is considered a marker of basal cell type origin of prostate cancer and is more common in metastatic prostate cancer and after androgen deprivation (30) . In previous studies, prostate epithelial cells have been transformed with DNA tumor viruses and murine prostate cancer cell lines have been derived from oncomice (31) . hTERT together with SV40T/t immortalizes human PEC and together with either Ha-Ras or c-Myc results in cells that grow in tissue culture.
However, unlike the lines developed herein, these PEC lines were unable to grow tumors after subcutaneous implantation or form metastasis in vivo (32) . cells has distinct requirements (33, 34) . Human fibroblasts can be transformed by two oncogenes (35) . Primary human cells can be immortalized by the introduction of the catalytic subunit of human telomerase reverse transcriptase (hTERT) and SV40 large-T to inactivate the pRb and p53 pathways (36) . Immortal human cells are converted into transformed cells with tumorigenic growth by the further induction of an oncogenic Ha-Ras allele and the SV40 early region oncoprotein small t antigen (37, 38, 35) . The requirements for transformation are cell type specific (34) . Human mammary epithelial cells immortalized by SV40 and hTERT undergo tumorigenic conversion with oncogenic Ras (36) or by the use of a mutant p53, a CDK4 mutant and cyclin D1 overexpression (39) . SV40 LT contributes to transformation though inactivation of p53 and pRb, as attested by siRNA analysis. Cautionary caveats to the use of these cell lines include the potential importance of the local prostate microenvironment in progression of prostate cancer, the capacity of the FVB murine strain background to enhance tumor progression (40) and the tendency of human prostate cancer metastasis to target bone rather than lung (41) . controversial, a subset of prostate cancer patients express ErbB2 and its pathway, and activated ErbB2 is sufficient to induce prostate cancer in transgenic mice (45, 46) . In vivo, the activating Ras mutation (Ha-Ras V12) induced low-grade PIN in mice when directed to prostate epithelial cells under the control of the minimal probasin promoter (47) .
The current studies identified oncogene-specific signatures in murine prostate epithelium that were recapitulated within human prostate cancer samples. Oncogene specific signatures have been proposed to exist within human prostate cancer (10) . In human breast cancer, the identification of tumor subsets with patterns of transcriptional and biological activity has allowed a deeper understanding of the disease. It has been anticipated that the identification of these patterns of gene function in otherwise heterogeneous biological material may enable the identification of targets for therapies and to thereby improve management of prostate cancer. The development herein of oncogene specific prostate cancer cell lines may be of value in developing targeted therapies for prostate cancer. 
